Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 13/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21596988 | 0.98 | EPHX1 (0.43) | EPHX1ACHEFAAHCA12CA1 | |
| SCHEMBL25362201 | 0.98 | EPHX1 (0.43) | EPHX1ACHEFAAHCA12CA1 | |
| SCHEMBL759928 | 0.94 | EPHX1 (0.37) | EPHX1ACHEFAAHCA12CA1 | |
| SCHEMBL759990 | 0.86 | ACHE (0.32) | EPHX1ACHE | |
| SCHEMBL21059108 | 0.82 | EPHX1 (0.60) | EPHX1ACHEFAAH | |
| SCHEMBL13278329 | 0.82 | ACHE (0.51) | EPHX1ACHECA12CA1CA2 | |
| SCHEMBL21059244 | 0.81 | EPHX1 (0.63) | EPHX1ACHEFAAH | |
| SCHEMBL29163511 | 0.81 | EPHX1 (0.63) | EPHX1ACHEFAAH | |
| SCHEMBL28804144 | 0.81 | EPHX1 (0.63) | EPHX1ACHEFAAH | |
| SCHEMBL17670555 | 0.81 | EPHX1 (0.40) | EPHX1ACHECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113277974-B | 2-phenylcyclopropylmethylamine derivative, and preparation method and use thereof | 上海科技大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-109071552-B | Degradation of cyclin dependent kinase 4/6(CDK4/6) by conjugation of CDK4/6 inhibitors to E3 ligase ligands and methods of use | 达纳－法伯癌症研究所公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-113277974-A | 2-phenylcyclopropylmethylamine derivative, and preparation method and use thereof | 上海科技大学 | 2021-08-20 | — | — | CN | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| CN-101389608-A | 5-HT7Receptor antagonists | ESTEVE LABOR DR (ES) | 2009-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | EPHX1 1930/4885ACHE 2857/4885FAAH 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.